Limits...
Profound thrombocytopenia after primary exposure to eptifibatide.

Norgard NB, Badgley BT - Drug Healthc Patient Saf (2010)

Bottom Line: A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,000 cells/mm(3)) within a few hours of receiving the drug.This case report discusses a patient who developed profound thrombocytopenia within hours of receiving eptifibatide for the first time.Profound thrombocytopenia is an uncommon but clinically important complication of eptifibatide.

View Article: PubMed Central - PubMed

Affiliation: University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA.

ABSTRACT
Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,000 cells/mm(3)) within a few hours of receiving the drug. This case report discusses a patient who developed profound thrombocytopenia within hours of receiving eptifibatide for the first time. The Naranjo algorithm classified the likelihood that this patient's thrombocytopenia was related to eptifibatide as probable. Profound thrombocytopenia is an uncommon but clinically important complication of eptifibatide. This case report emphasizes the importance of monitoring platelet counts routinely at baseline and within 2-6 hours of eptifibatide administration.

No MeSH data available.


Related in: MedlinePlus

Timeline of platelet count during index hospitalization.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108691&req=5

f1-dhps-2-163: Timeline of platelet count during index hospitalization.

Mentions: Approximately four hours post-percutaneous coronary intervention and eptifibatide initiation, the patient developed a precipitous thrombocytopenia, with her platelet count dropping by over 90% from baseline to 17 ×109/L (see Figure 1). A peripheral blood smear showed no signs of platelet clumping, ruling out pseudothrombocytopenia. The rest of her complete blood count at this time included hemoglobin 10.7 g/dL, hematocrit 31.3%, and white blood cell count 6 × 109/L. Eptifibatide was subsequently discontinued. The patient’s platelet level reached its nadir (13 × 109/L) approximately nine hours post-eptifibatide initiation. The patient’s platelet count gradually climbed, and was 71 ×109/L at the time of discharge (approximately 80 hours post-eptifibatide initiation). The patient showed no signs of active bleeding, bruises, ecchymosis, or petechiae during the hospitalization.


Profound thrombocytopenia after primary exposure to eptifibatide.

Norgard NB, Badgley BT - Drug Healthc Patient Saf (2010)

Timeline of platelet count during index hospitalization.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108691&req=5

f1-dhps-2-163: Timeline of platelet count during index hospitalization.
Mentions: Approximately four hours post-percutaneous coronary intervention and eptifibatide initiation, the patient developed a precipitous thrombocytopenia, with her platelet count dropping by over 90% from baseline to 17 ×109/L (see Figure 1). A peripheral blood smear showed no signs of platelet clumping, ruling out pseudothrombocytopenia. The rest of her complete blood count at this time included hemoglobin 10.7 g/dL, hematocrit 31.3%, and white blood cell count 6 × 109/L. Eptifibatide was subsequently discontinued. The patient’s platelet level reached its nadir (13 × 109/L) approximately nine hours post-eptifibatide initiation. The patient’s platelet count gradually climbed, and was 71 ×109/L at the time of discharge (approximately 80 hours post-eptifibatide initiation). The patient showed no signs of active bleeding, bruises, ecchymosis, or petechiae during the hospitalization.

Bottom Line: A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,000 cells/mm(3)) within a few hours of receiving the drug.This case report discusses a patient who developed profound thrombocytopenia within hours of receiving eptifibatide for the first time.Profound thrombocytopenia is an uncommon but clinically important complication of eptifibatide.

View Article: PubMed Central - PubMed

Affiliation: University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, USA.

ABSTRACT
Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist used to reduce the incidence of ischemic events in patients with acute coronary syndromes and those undergoing percutaneous coronary intervention. A minority of patients given eptifibatide develop acute, profound thrombocytopenia (<20,000 cells/mm(3)) within a few hours of receiving the drug. This case report discusses a patient who developed profound thrombocytopenia within hours of receiving eptifibatide for the first time. The Naranjo algorithm classified the likelihood that this patient's thrombocytopenia was related to eptifibatide as probable. Profound thrombocytopenia is an uncommon but clinically important complication of eptifibatide. This case report emphasizes the importance of monitoring platelet counts routinely at baseline and within 2-6 hours of eptifibatide administration.

No MeSH data available.


Related in: MedlinePlus